comparemela.com
Home
Live Updates
FDA Approval Insights: Ponatinib in Ph+ ALL : comparemela.com
FDA Approval Insights: Ponatinib in Ph+ ALL
Dr Jabbour expands on the FDA approval of ponatinib for patients with Ph-positive ALL, the agent’s mechanism of action, and data from the PhALLCON trial.
Related Keywords
Texas ,
United States ,
Houston ,
Philadelphia ,
Pennsylvania ,
Elias Jabbour ,
Courtney Flaherty ,
Linkedin ,
Twitter ,
University Of Texas Md Anderson Cancer Center ,
Division Of Cancer Medicine ,
Facebook ,
Department Of Leukemia ,
Live On Air ,
Cancer Medicine ,
Cancer Center ,
Onclive On Air ,
Apple Podcasts ,
Google Podcasts ,
Amazon Music ,
Fda Approval Of Ponatinib ,
Patients With Ph Positive All ,
Phallcon Trial ,
comparemela.com © 2020. All Rights Reserved.